Cancer Research UK (CRUK) has reported record levels of investment for its spinout portfolio, with the ‘most successful financial year’ recorded to date.
UK-based Achilles Therapeutics has announced the closing of its £100m Series B financing round, which was led by new investor RA Capital Management and founding investor Syncona.